Euroz Hartleys research: Two major catalysts approach

Equity research from Euroz Hartleys examines Cynata's clinical pipeline and investment outlook ahead of two pivotal trial readouts in Q2 2026. The report maintains a Speculative Buy recommendation with a A$0.90 price target (risked valuation) and A$1.80 unrisked valuation, highlighting the Phase 2 acute graft-versus-host disease and Phase 3 osteoarthritis programs as "the most significant catalysts for the company in several years."

Published 30 January 2026 by Research Analyst Seth Lizee.